deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT03532542

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen

Sponsor: Sarepta Therapeutics, Inc.

Conditions Duchenne Muscular Dystrophy
Interventions Casimersen Golodirsen
Updated 30 times since 2018 Last updated: Sep 13, 2024 Started: Aug 2, 2018 Primary completion: Jul 26, 2023 Completion: Jul 26, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The trial was stopped to reduce the clinical trial burden on participants while ensuring continued treatment via a post-trial access program with commercially available casimersen and golodirsen. Study was not terminated due to safety concerns.

Other terminated trials from Sarepta Therapeutics, Inc.

More terminations from Sarepta Therapeutics, Inc.

Other Duchenne Muscular Dystrophy trials with similar outcome

Browse all Duchenne Muscular Dystrophy trials

This PHASE3 trial investigates Duchenne Muscular Dystrophy and is currently terminated or withdrawn. Sarepta Therapeutics, Inc. leads this study, which shows 30 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Oct 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Sep 2024 — Oct 2024 [monthly]

    Terminated PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  5. Sep 2023 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

▶ Show 25 earlier versions

  1. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Enrolling By Invitation → Active Not Recruiting

  2. Sep 2022 — Aug 2023 [monthly]

    Enrolling By Invitation PHASE3

  3. Jul 2022 — Sep 2022 [monthly]

    Enrolling By Invitation PHASE3

  4. Jun 2022 — Jul 2022 [monthly]

    Enrolling By Invitation PHASE3

  5. Jan 2022 — Jun 2022 [monthly]

    Enrolling By Invitation PHASE3

  6. Oct 2021 — Jan 2022 [monthly]

    Enrolling By Invitation PHASE3

  7. Feb 2021 — Oct 2021 [monthly]

    Enrolling By Invitation PHASE3

  8. Jan 2021 — Feb 2021 [monthly]

    Enrolling By Invitation PHASE3

  9. Dec 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE3

  10. Aug 2020 — Dec 2020 [monthly]

    Enrolling By Invitation PHASE3

  11. Jul 2020 — Aug 2020 [monthly]

    Enrolling By Invitation PHASE3

  12. Apr 2020 — Jul 2020 [monthly]

    Enrolling By Invitation PHASE3

  13. Mar 2020 — Apr 2020 [monthly]

    Enrolling By Invitation PHASE3

  14. Jan 2020 — Mar 2020 [monthly]

    Enrolling By Invitation PHASE3

  15. Dec 2019 — Jan 2020 [monthly]

    Enrolling By Invitation PHASE3

  16. Nov 2019 — Dec 2019 [monthly]

    Enrolling By Invitation PHASE3

  17. Oct 2019 — Nov 2019 [monthly]

    Enrolling By Invitation PHASE3

  18. Aug 2019 — Oct 2019 [monthly]

    Enrolling By Invitation PHASE3

  19. Jun 2019 — Aug 2019 [monthly]

    Enrolling By Invitation PHASE3

  20. Apr 2019 — Jun 2019 [monthly]

    Enrolling By Invitation PHASE3

  21. Mar 2019 — Apr 2019 [monthly]

    Enrolling By Invitation PHASE3

  22. Dec 2018 — Mar 2019 [monthly]

    Enrolling By Invitation PHASE3

  23. Nov 2018 — Dec 2018 [monthly]

    Enrolling By Invitation PHASE3

  24. Oct 2018 — Nov 2018 [monthly]

    Enrolling By Invitation PHASE3

    Status: Not Yet Recruiting → Enrolling By Invitation

  25. Jun 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sarepta Therapeutics, Inc.
Data source: Sarepta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Barcelona, Spain , Boston, United States , Brno, Czechia , Calgary, Canada , Chicago, United States , Cincinnati, United States , Columbus, United States , Cona, Italy and 38 more locations